Events in AML-HR trial by FLA versus ADE randomization
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | FLA . | ADE . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 7 | 5 | — | — | |
| Resistant disease | 31 | 31 | — | — | |
| CR rate | 61 | 63 | 1.09 (0.63-1.87) | .8 | |
| Outcome after CR* | |||||
| Death in CR | 34 | 12 | — | .1 | |
| Relapse rate | 65 | 67 | — | .6 | |
| Disease-free survival* | 23 | 29 | 1.24 (0.87-1.78) | .2 | |
| Overall survival* | 16 | 27 | 1.33 (1.01-1.77) | .05 | |
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | FLA . | ADE . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 7 | 5 | — | — | |
| Resistant disease | 31 | 31 | — | — | |
| CR rate | 61 | 63 | 1.09 (0.63-1.87) | .8 | |
| Outcome after CR* | |||||
| Death in CR | 34 | 12 | — | .1 | |
| Relapse rate | 65 | 67 | — | .6 | |
| Disease-free survival* | 23 | 29 | 1.24 (0.87-1.78) | .2 | |
| Overall survival* | 16 | 27 | 1.33 (1.01-1.77) | .05 | |
For FLA, the number of patients randomly assigned to the group was 126; for ADE, n = 124.
— indicates not calculated.
Outcome at 4 years is given for time-to-event end points.